LINDA A. JOHNSON AP Business Writer TRENTON, N.J. (AP) — Drugmaker Bristol-Myers Squibb Co., seeking to bolster revenue during a crucial period, said Monday it has struck a deal with a Japanese partner to extend their partnership on one drug by 2½ years and to collaborate on two others. New York-based Bristol-Myers and Otsuka Pharmaceutical Co. Ltd. are prolonging until 2015 a deal to share revenue and marketing costs for the blockbuster psychiatric drug Abilify, which Otsuka discovered. That partnership was to end in November 2012, about six months after Bristol’s top seller, blood thinner Plavix, gets generic competition. Plavix had just under $5 billion in sales last year and is one of the best-selling prescription medicines in the world. Analysts and investors had been worried that Bristol-Myers revenues would fall sharply in 2013 as a result of the plunge in Plavix revenues. The company said with the new moves, its earnings per share will be boosted by 30 cents each in 2013 and 2014. Bristol-Myers also confirmed its previous earnings forecast of $1.58 to $1.73 for this year and confirmed it expects earnings per share to grow by 15 percent, excluding charges, from 2007 through 2010. “This is one of the more significant levers we can pull to improve our business outlook in 2013,” said Bristol-Myers spokeswoman Tracy Furey. Chief Operating Officer Lamberto Andreotti said in the statement the deal would help “transition us to a period of growth in 2014 and beyond” and that the company’s balance sheet allows it to pursue other business development opportunities. Otsuka and Bristol-Myers have shared the marketing of Abilify since 1999. The drug is approved for schizophrenia, bipolar disorder and depression. With the new agreement, the Abilify deal will run until it loses patent protection around April 2015. Company officials would not say how much that would increase revenue from Abilify. It had about $3 billion in global sales in 2008, 65 percent of which went to Bristol-Myers Squibb, which also bore all marketing and continuing research costs. The two companies expect a decision late this year on whether they can also market Abilify in the U.S. for irritability in 16- and 17-year-olds with autism. Under the new deal, starting next January Bristol-Myers’ share of Abilify revenue will drop steadily to 51.5 percent in 2012, but Otsuka will pay 30 percent of marketing and further research costs. Otsuka will pay half those costs from 2013 through the loss of patent protection in 2015; during those three years, Bristol-Myers will get half of all sales up to $2.7 billion and a smaller share of any additional sales. Meanwhile, the companies agreed to share revenue and marketing and further development costs for two Bristol cancer drugs, Sprycel and Ixempra. Sprycel, which had about $400 million in 2008 sales, is approved for treating two types of leukemia and is in final-stage testing for prostate cancer. Ixempra, launched at the end of 2007, had about $100 million in sales last year. It is approved for treating advanced breast cancer after patients have failed on other types of cancer drugs, and is in early human testing for prostate cancer. Starting in 2010, Otsuka will shoulder some marketing expenses for Sprycel in the U.S., Europe and Japan. From then until 2020, Otsuka will receive a percentage of annual sales for the two drugs, with that percentage declining as sales rise.